Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aß protofibril antibody.

Swanson, Chad J; Zhang, Yong; Dhadda, Shobha; Wang, Jinping; Kaplow, June; Lai, Robert Y K; Lannfelt, Lars; Bradley, Heather; Rabe, Martin; Koyama, Akihiko; Reyderman, Larisa; Berry, Donald A; Berry, Scott; Gordon, Robert; Kramer, Lynn D; Cummings, Jeffrey L

Swanson, Chad J; Zhang, Yong; Dhadda, Shobha; Wang, Jinping; Kaplow, June; Lai, Robert Y K; Lannfelt, Lars; Bradley, Heather; Rabe, Martin; Koyama, Akihiko; Reyderman, Larisa; Berry, Donald A; Berry, Scott; Gordon, Robert; Kramer, Lynn D; Cummings, Jeffrey L.

Afiliação

Swanson CJ; Eisai Inc., Woodcliff Lake, NJ, USA.
Zhang Y; Eisai Inc., Woodcliff Lake, NJ, USA.
Dhadda S; Eisai Inc., Woodcliff Lake, NJ, USA.
Wang J; Eisai Inc., Woodcliff Lake, NJ, USA.
Kaplow J; Eisai Inc., Woodcliff Lake, NJ, USA.
Lai RYK; Eisai Ltd., Hatfield, UK.
Lannfelt L; BioArctic AB, Warfvinges väg 35, SE-112 51, Stockholm, Sweden.
Bradley H; Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
Rabe M; Eisai Inc., Woodcliff Lake, NJ, USA.
Koyama A; Eisai Inc., Woodcliff Lake, NJ, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, NJ, USA.
Berry DA; Eisai Inc., Woodcliff Lake, NJ, USA.
Berry S; Berry Consultants, LLC, Austin, TX, USA.
Gordon R; Berry Consultants, LLC, Austin, TX, USA.
Kramer LD; Eisai Ltd., Hatfield, UK.
Cummings JL; Eisai Inc., Woodcliff Lake, NJ, USA.

Alzheimers Res Ther ; 14(1): 70, 2022 May 21.

Article em En | MEDLINE | ID: mdl-35598024

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Alzheimers Res Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google